Leukemia drug shows promise for treating a childhood brain cancer
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego. (Source: World Pharma News)
Source: World Pharma News - September 23, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Chronic Myeloid Leukemia: 5 Things to Know Chronic Myeloid Leukemia: 5 Things to Know
In the wake of the tyrosine kinase inhibitor revolution, where is the treatment of CML headed?Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
Promising Blood Test Could Help to Predict Breast Cancer Recurrence
Doctors have gotten much better at detecting and treating breast cancer early. Drug and chemotherapy regimens to control tumors have gotten so effective, in fact, that in some cases, surgery is no longer necessary. In up to 30% of cases of early-stage breast cancer treated before surgery, doctors can’t find evidence of cancer cells in postoperative biopsies. The problem, however, is that there is currently no reliable way to tell which cancers have been pushed into remission and which ones have not.
That’s where an easy identifier, like a blood test, could transform the way early stage breast cancer is treated....
Source: TIME: Health - August 8, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized blood tests Breast Cancer Source Type: news
Chronic Leukemia | Medscape Chronic Leukemia | Medscape
Chronic leukemias -- chronic myeloid leukemia and chronic lymphocytic leukemia -- occur mostly in adults and are extremely rare in children and young persons. Chronic lymphocytic leukemia has the highest familial incidence of the leukemias. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news
Value of Second-Generation TKIs Must Be Considered for CML Patients
Researchers looked at second-generation tyrosine kinase inhibitors at their current prices to test treatment value for patients with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 24, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
SIRT1 plays key role in chronic myeloid leukemia to aid persistence of leukemic stem cells
(University of Alabama at Birmingham) Patients with chronic myeloid leukemia are treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure. In a study published in the Journal of Clinical Investigation, researchers show how the stress-responsive protein SIRT1 plays important roles in maintaining the regenerative potential of CML leukemic stem cells and promoting leukemia development in CML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 10, 2019 Category: Biology Source Type: news
Diamonds Are Forever, but TKIs in CML Don't Have to Be Diamonds Are Forever, but TKIs in CML Don't Have to Be
Patients with chronic myeloid leukemia who undergo lifelong therapy with tyrosine kinase inhibitors have excellent outcomes. But treatment may not have to be forever.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Reasons for TKI Discontinuation ID'd in Chronic Myeloid Leukemia
TUESDAY, April 16, 2019 -- For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online March 16... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2019 Category: Pharmaceuticals Source Type: news
How 'sleeper cell' cancer stem cells are maintained in chronic myelogenous leukemia
(University of Alabama at Birmingham) Even when chronic myelogenous leukemia is in remission, 'sleeper cell,' quiescent leukemic stem cells are maintained in microenvironments in the bone marrow. This maintenance is poorly understood. Researchers now describe how niche-specific expression of a particular chemokine by a particular type of bone marrow cell controls quiescence of these treatment-resistant leukemic stem cells. The chemokine is CXCL12, and the particular bone marrow cells expressing it are mesenchymal stromal cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses... (Source: The Scientist)
Source: The Scientist - February 19, 2019 Category: Science Tags: The Scientist The Marketplace Source Type: news
LZTR1 is a regulator of RAS ubiquitination and signaling
In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors. Knockdown of the Drosophila LZTR1 ortholog CG3711 resulted in a Ras-dependent gain-of-function phenotype. Endogenous human LZTR1 associates with the main RAS isoforms. Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V...
Source: ScienceNOW - December 6, 2018 Category: Science Authors: Bigenzahn, J. W., Collu, G. M., Kartnig, F., Pieraks, M., Vladimer, G. I., Heinz, L. X., Sedlyarov, V., Schischlik, F., Fauster, A., Rebsamen, M., Parapatics, K., Blomen, V. A., Müller, A. C., Winter, G. E., Kralovics, R., Brummelkamp, T. R., Mlod Tags: Cell Biology, Medicine, Diseases reports Source Type: news
Leukemic Arthritis and Severe Hypercalcemia in CML Leukemic Arthritis and Severe Hypercalcemia in CML
This case demonstrates potential manifestations of leukemic arthritis and severe hypercalcemia in patients with advanced chronic myeloid leukemia.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Genoptix Launches FDA-Authorized BCR-ABL MRDx(R) TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna(R) (nilotinib)
CARLSBAD, Calif., Sept. 4, 2018 -- (Healthcare Sales & Marketing Network) -- Genoptix, Inc., a leading oncology diagnostic laboratory, announces the immediate availability of a proprietary, FDA-authorized BCR-ABL MRDx® TFR Monitoring Test for patients... Diagnostics, Oncology, Product Launch Genoptix, BCR-ABL MRDx, TFR Monitoring Test, chronic myeloid leukemia, Tasigna (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 4, 2018 Category: Pharmaceuticals Source Type: news
CML Following Treatment for Primary Neoplasms CML Following Treatment for Primary Neoplasms
This study aimed to characterize the clinical presentation and pathologic features of therapy-related chronic myeloid leukemia. Do they differ significantly from those of primary CML?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Imatinib-induced Fulminant Liver Failure in CML Imatinib-induced Fulminant Liver Failure in CML
Acute liver failure can be a fatal adverse effect of chronic myeloid leukemia treatment with imatinib. Is liver transplant a viable option for these patients?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
